GlassScriptPhysician profile
Scott R Anagnoste
NPI 1487652566
$1,591.85
in general payments reported to CMS, 2019-2025
10 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $101 · 2021: $64.89 · 2022: $187 · 2023: $253 · 2024: $263 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $784.28 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $339.86 | 2019-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $120.18 | 2023 | Syfovre |
| Sandoz INC. | $88.93 | 2024-2025 | Cimerli |
| Astellas Pharma US INC | $85.63 | 2024-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $63.39 | 2019-2020 | |
| Coherus Oncology, INC. | $44.33 | 2022 | |
| Alimera Sciences, INC. | $27.92 | 2020 | |
| Viiv Healthcare Company | $20.09 | 2024 | Cabenuva |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Anagnoste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.